BMYMirati Therapeutics Inc.Finished
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
Advanced or Metastatic Solid Malignancies
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2/3
- Patients
- 49 (final count)
- Started
- Jun 29, 2021
- Main results expected
- Apr 21, 2025
- Fully finished
- Sep 25, 2025
- Results posted
- Aug 4, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Treatment Related Adverse Events.
Measured over: Approximately up to 80.5 weeks
Number of Participants With Treatment Related Adverse Events Which Lead to Study Drug Discontinuation
Measured over: Approximately up to 80.5 weeks
Number of Participants With Clinically Significant Laboratory Abnormalities
Measured over: Approximately up to 80.5 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04887870 · record last updated 2026-08-04 · checked 2026-11-09 15:47 UTC